Showing 2201-2210 of 3039 results for "".
- Anthem Blue Cross Blue Shield Now Covering Avedro’s Corneal Cross-Linking Procedurehttps://modernod.com/news/anthem-blue-cross-blue-shield-now-covering-avedros-corneal-cross-linking-procedure/2479624/Avedro announced that Anthem, the largest member of the Blue Cross Blue Shield Association, has issued a positive coverage policy for Avedro’s FDA-approved corneal cross-linking procedure bringing the total number of
- Lynx Inventory System Now Customized for Retina Specialistshttps://modernod.com/news/lynx-inventory-system-now-customized-for-retina-specialists/2479638/McKesson announced that Lynx, its customizable, cloud-based medication inventory management system for specialty medical practices, has new features designed especially for delivering injectable medication therapies in retina practices. These customizations for retina specialists ensure that each
- Warby Parker Eyewear Now Available to People Enrolled in UnitedHealthcare Medicare Advantage Planshttps://modernod.com/news/warby-parker-eyewear-now-available-to-people-enrolled-in-unitedhealthcare-medicare-advantage-plans/2479652/For the first time, Warby Parker is accepting Medicare insurance. The company’s designer prescription eyewear is available to approximately 2 million people enrolled in UnitedHealthcare Medicare Advantage plans, either online or at more than 80 Warby Parker stores nationwide, according to a
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p
- NORA and Concussion Legacy Foundation Offer New Educational Resource on Vision Problems and Symptoms Following a Concussionhttps://modernod.com/news/nora-and-concussion-legacy-foundation-offer-new-educational-resource-on-vision-problems-and-symptoms-following-a-concussion/2479702/Following a concussion or other traumatic brain injury (TBI) there is often an interruption in communication between the eyes and the brain. Studies show that at least 50 percent of TBI patients suffer from visual dysfunctions, with one such study finding a 90 percent incidence of post-trauma vis
- First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitishttps://modernod.com/news/first-patient-screened-in-mallinckrodt-phase-4-trial-of-h-p-acthar-gel-for-severe-noninfectious-intermediate-uveitis-posterior-uveitis-or-panuveitis/2479736/Mallinckrodt confirmed screening of the first patient in the company’s phase 4, multicenter, multiple-dose, open label study to assess the effects of H.P. Acthar Gel as
- Alcon Expands Surgical Offerings with Portfolio of Mydriatic, Cycloplegic, Diagnostic, and Anesthetic Productshttps://modernod.com/news/alcon-expands-surgical-offerings-with-portfolio-of-mydriatic-cycloplegic-diagnostic-and-anesthetic-products/2479801/Alcon announced that it is expanding its surgical offerings with the addition of a group of products fundamental to many ophthalmic procedures done in the clinic and operating room. These products, which include mydriatic, cycloplegic, diagnostic, and anesthetic products, were transferred from Al
- Optovue Showcases First OCT Angiography Metrics and Non-Contact Method for Corneal Measurements at Vision Expo Westhttps://modernod.com/news/optovue-showcases-worlds-first-oct-angiography-metrics-and-non-contact-method-for-corneal-measurements-at-vision-expo-west/2479832/Optovue showcased its AngioAnalytics platform, the world’s first OCT angiography (OCTA) blood vessel measurement technology to help clinicians manage diseases that cause progressive blindness, and 3D PAR, its 3-dimensional projection artifact removal software at Vision Expo West 2018. The
- First FDA-Approved Iris Prosthesis Now Available in the United Stateshttps://modernod.com/news/veo-ophthalmics-launches-customflex-artificialiris-in-the-united-states/2479835/VEO Ophthalmics announced the launch of the ‘Customflex ArtificialIris,’ the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from cong
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site